Loading...

ACLX ARCELLX INC Product Launches 8-K Filing

RCLL

CLX

ARCELLX INC

(ACLX)

2024 8-K

Merger Announcement

Positive Clinical Data

Financial Results Update

Earnings Releases

Product Expansion

Financial Statements

Financial Results

Investor Webcast

Positive Study Results

Financial Results

Clinical Data Release

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Reports

Dismissal and Appointment o...

Earnings Reports

Termination of Lease Agreement

Stock Purchase Agreement

Webcast Investor Relations ...

Clinical Data Announcement

Amendment to Collaboration ...

Financial Results Announcement

Clinical Data Release

Financial Results Announcement

Other Special Situation

Annual Meeting of Stockholders

Equity Offering

Results of Operations and F...

Financial Results and Annua...

Collaboration Agreement and...

External Links:

Arcellx, Inc. announced positive data from its Phase 2 iMMagine-1 study for anitocabtagene autoleucel in multiple myeloma patients and details about an upcoming presentation at the American Society of Hematology Annual Meeting.

AI Assistant

ARCELLX INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.